Jun 2026 (Q2 FY26) — Aug 12, 2026
Milestone Pharmaceuticals Q2 FY26 — Cardamyst Launch Progress and AFib-RVR Phase 3 Initiation
Read the full callMilestone Pharmaceuticals (MIST) earnings
- Jun 2026
- Jun 2026 (Q2 FY26)
- Dec 2025
Milestone Pharmaceuticals earnings: last reported Wed, 12 Aug 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 0.56 | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. The year-earlier figure was zero or a loss, so no percentage is shown. | |
| Operating margin | -4585.0 | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. | |
| Net profit | -28.6 | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. The year-earlier figure was zero or a loss, so no percentage is shown. |
Price
$0.7 −1.41% · −$0.01
Performance −63.9% 1Y
1Y: $1.94 on 17 Oct 2025 → $0.7. High $2.95 (11 Dec 2025), low $0.7 (19 Oct 2026).
- Previous close
- $0.71
- 52-week range
- $0.7 – $2.95
- One year
- −64.82%
Overview
- Symbol
- MIST
- Sector
- Health Care
- Exchange
- US
- Currency
- USD
Call summaries
Every analysed call
Milestone Pharmaceuticals earnings calls (MIST)
Financials
What the filings say
Net profit, year on year: −121% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | — | — | 0 | 0 | — | — | 0 | 1 |
| Expenses | — | — | 21 | 13 | — | — | 24 | 26 |
| Operating profit | -10 | -12 | -21 | -13 | -12 | -17 | -24 | -26 |
| Operating margin | — | — | — | — | — | — | −9942.4% | −4585.0% |
| Interest | 1 | 1 | 1 | 1 | 1 | 1 | 4 | 5 |
| Net profit | -9 | -12 | -21 | -13 | -12 | -17 | -26 | -29 |
| EPS ($ per share) | -0.14 | — | -0.31 | -0.20 | -0.12 | — | -0.20 | -0.21 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Equity capital | 2 | 226 | 252 | 252 | 274 | 261 | 288 | 353 |
| Reserves | -58 | -113 | -163 | -208 | -266 | -326 | -368 | -431 |
| Total liabilities | 5 | 9 | 7 | 7 | 8 | 58 | 62 | 72 |
| Fixed assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Investments | 0 | — | 70 | 0 | 57 | 52 | 44 | 33 |
| Total assets | 88 | 123 | 150 | 120 | 74 | 75 | 75 | 114 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | -21 | -51 | -51 | -33 | -52 | -46 | -29 | -49 |
| Cash from investing | 16 | -0 | -70 | 70 | -57 | 5 | 8 | 11 |
| Cash from financing | 80 | 85 | 73 | 5 | 3 | 48 | 32 | 86 |
| Net cash flow | 75 | 34 | -48 | 42 | -107 | 6 | 12 | 48 |
| Capital expenditure | -0 | -0 | — | — | -0 | -0 | -0 | -0 |
| Free cash flow | -21 | -52 | — | — | -53 | -47 | -29 | -49 |
Insider filings
24 filings between Dec 9, 2025 and Apr 16, 2026.
Open market
decisions to buy or sellPurchases
None
No insider bought shares.
Sales
$1.18M
13 sales by 5 insiders
23% filed under a 10b5-1 plan — scheduled in advance, not decided on the day
Compensation
not trading decisions- 5
- Award — granted as compensation
- 5
- Option exercise — converted options into shares
Also filed: 1 gift.
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| Oliveto Joseph | — | $555.7K | Apr 16, 2026 |
| Hasija Amit | — | $158.2K | Jan 26, 2026 |
| Bharucha David | — | $158.2K | Jan 26, 2026 |
| Nelson Jeffrey Edward | — | $158.2K | Jan 26, 2026 |
| Muller Lorenz | — | $145.9K | Jan 26, 2026 |
Latest filings (31)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Apr 16, 2026 | Oliveto Joseph President and CEO | Sale 10b5-1 plan | 36,500 | $82.5K |
| Jan 26, 2026 | Bharucha David Chief Medical Officer | Option exercise | 20,100 | — |
| Jan 26, 2026 | Oliveto Joseph President and CEO | Option exercise | 66,600 | — |
| Jan 26, 2026 | Oliveto Joseph President and CEO | Sale | 34,523 | $66.6K |
| Jan 26, 2026 | Muller Lorenz Chief Commercial Officer | Option exercise | 20,100 | — |
| Jan 26, 2026 | Muller Lorenz Chief Commercial Officer | Sale | 11,180 | $21.6K |
| Jan 26, 2026 | Hasija Amit CFO & EVP of Corp. Development | Option exercise | 20,100 | — |
| Jan 26, 2026 | Hasija Amit CFO & EVP of Corp. Development | Sale | 12,245 | $23.6K |
| Jan 26, 2026 | Bharucha David Chief Medical Officer | Sale | 12,245 | $23.6K |
| Jan 26, 2026 | Nelson Jeffrey Edward Chief Operating Officer | Option exercise | 20,100 | — |
| Jan 26, 2026 | Nelson Jeffrey Edward Chief Operating Officer | Sale | 12,245 | $23.6K |
| Jan 8, 2026 | Oliveto Joseph President and CEO | Sale 10b5-1 plan | 43,000 | $96.8K |
| Jan 7, 2026 | Oliveto Joseph President and CEO | Sale 10b5-1 plan | 500 | $1.1K |
| Dec 15, 2025 | Hasija Amit CFO & EVP of Corp. Development | Sale | 58,007 | $134.6K |
| Dec 15, 2025 | Bharucha David Chief Medical Officer | Sale | 58,007 | $134.6K |
| Dec 15, 2025 | Nelson Jeffrey Edward Chief Operating Officer | Sale | 58,007 | $134.6K |
| Dec 15, 2025 | Oliveto Joseph President and CEO | Sale | 133,054 | $308.7K |
| Dec 15, 2025 | Muller Lorenz Chief Commercial Officer | Sale | 53,566 | $124.3K |
| Dec 12, 2025 | Muller Lorenz Chief Commercial Officer | Award | 100,000 | — |
| Dec 12, 2025 | Nelson Jeffrey Edward Chief Operating Officer | Award | 100,000 | — |
| Dec 12, 2025 | Oliveto Joseph President and CEO | Award | 280,000 | — |
| Dec 12, 2025 | Bharucha David Chief Medical Officer | Award | 100,000 | — |
| Dec 12, 2025 | Hasija Amit CFO & EVP of Corp. Development | Award | 100,000 | — |
| Dec 9, 2025 | Muller Lorenz Chief Commercial Officer | Gift | 25,000 | $0 |
| Jul 11, 2025 | Muller Lorenz Chief Commercial Officer | Award | 66,666 | — |
| Jul 11, 2025 | Bharucha David Chief Medical Officer | Award | 53,333 | — |
| Jul 11, 2025 | Oliveto Joseph President and CEO | Award | 66,666 | — |
| Jul 11, 2025 | PAPA JOSEPH C Director | Award | 100,000 | — |
| Jul 11, 2025 | Liebert Debra K. Director | Award | 16,666 | — |
| Jul 11, 2025 | Wills Robert James Director | Award | 50,000 | — |
| Jul 11, 2025 | Hasija Amit CFO & EVP of Corp. Development | Award | 50,000 | — |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for Milestone Pharmaceuticals Inc.
Free account. Everything above stays public.
Write why you follow Milestone Pharmaceuticals Inc. and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading